Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822952 · ClinicalTrials.gov registry record
Prostate Mechanical Imager (PMI) Clinical Bridging Study
A clinical trial of Prostatic Neoplasms and Prostatic Hyperplasia, sponsored by Artann Laboratories.
- Completed
- Registry status
- 71
- Enrollment target
- 5
- Study locations
NCT00822952: Completed study of Prostatic Neoplasms and Prostatic Hyperplasia, sponsored by Artann Laboratories.
NCT00822952 is a study of Prostatic Neoplasms and Prostatic Hyperplasia that has completed, run by Artann Laboratories. The registered enrollment target is 71 participants, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00822952, a study of Prostatic Neoplasms and Prostatic Hyperplasia, has completed, sponsored by Artann Laboratories.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite elasticity images of the prostate.
Conditions Studied
Study Locations (5)
Minnesota
- University of Minnesota/VA Medical Center - Minneapolis
- Mayo Clinic - Rochester
New Jersey
- Robert Wood Johnson Medical Center - New Brunswick
New York
- AccuMed Research Associates - Garden City
Pennsylvania
- Urology Associates of Lancaster - Lancaster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-09 |
What the finished NCT00822952 record still lists
NCT00822952 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00822952 lists 5 locations in 4 states (Minnesota, New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT00822952 about?
NCT00822952 is a clinical study titled "Prostate Mechanical Imager (PMI) Clinical Bridging Study". The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite elasticity images of the prostate.
What is the current status of trial NCT00822952?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2008-10. Estimated completion is 2009-09.
What conditions does trial NCT00822952 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Prostatic Hyperplasia.
Who is sponsoring clinical trial NCT00822952?
This trial is sponsored by Artann Laboratories, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00822952 being conducted?
This trial has 5 study locations across Minnesota, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00822952's enrollment target sits among peer trials
71 44th of 65 higher than 22 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia